Frederieke A. Dijkstra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Frederieke A. Dijkstra has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Boudewijn van Etten
Department of Surgery University of Groningen, University Medical Center Groningen Groningen The Netherlands
14 shared publications - Jan Willem Haveman
Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
14 shared publications - Anne M. van der Waaij
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 1
13 shared publications - Dominic J. Robinson
Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands
13 shared publications - Gert Jan Meersma
Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. 1
13 shared publications - Gursah Kats-Ugurlu
Department of Pathology and Medical Biology University Medical Centre Groningen Groningen The Netherlands
13 shared publications
Latest Publications
- Open Access
- 23 August 2026
- Published by Wiley in Anz Journal of Surgery
Roux‐en‐Y Reconstruction After Esophagectomy for Postoperative Functional Complaints: A Case Series
Background: Esophagectomy with gastric conduit reconstruction is associated with functional complaints impacting quality of life in approximately half of patients, including delayed gastric emptying and reflux. Current management strategies have limited effect, and no standard surgical procedure exists to address these debilitating symptoms. Roux‐en‐Y reconstruction has emerged as a potential solution by creating duodenal diversion, promoting gastric conduit emptying, and eliminating the reflux of bile and pancreatic secretions into the gastric conduit. Methods: We report a case series of nine patients who underwent Roux‐en‐Y reconstruction with a gastric conduit‐jejunostomy after esophagectomy due to functional complaints between 2015 and 2024 who had at least a median follow‐up of 1 year. Results: Nine patients underwent Roux‐en‐Y reconstruction. Primary indications included obstructive symptoms ( n = 8), redundant gastric conduit ( n = 8), weight loss ( n = 7), bile reflux ( n = 5), and gastro‐esophageal reflux ( n = 1). All procedures were completed successfully with one Clavien–Dindo Grade IIIb complication (fascial dehiscence). No Grade 4 or 5 complications were observed. At 3‐month follow‐up, complete symptom resolution was achieved in six out of nine patients (67%). Complete symptom resolution at 1 year follow‐up was achieved in eight out of nine patients (89%). Conclusion: Substantial symptom improvement and acceptable and transient postoperative morbidity indicate that Roux‐en‐Y reconstruction is a viable treatment option for patients with persistent functional complaints following esophagectomy with gastric conduit reconstruction.
- 23 August 2026
- Published by Wiley in Anz Journal of Surgery
Open AccessRoux‐en‐Y Reconstruction After Esophagectomy for Postoperative Functional Complaints: A Case Series
Background: Esophagectomy with gastric conduit reconstruction is associated with functional complaints impacting quality of life in approximately half of patients, including delayed gastric emptying and reflux. Current management strategies have limited effect, and no standard surgical procedure exists to address these debilitating symptoms. Roux‐en‐Y reconstruction has emerged as a potential solution by creating duodenal diversion, promoting gastric conduit emptying, and eliminating the reflux of bile and pancreatic secretions into the gastric conduit. Methods: We report a case series of nine patients who underwent Roux‐en‐Y reconstruction with a gastric conduit‐jejunostomy after esophagectomy due to functional complaints between 2015 and 2024 who had at least a median follow‐up of 1 year. Results: Nine patients underwent Roux‐en‐Y reconstruction. Primary indications included obstructive symptoms ( n = 8), redundant gastric conduit ( n = 8), weight loss ( n = 7), bile reflux ( n = 5), and gastro‐esophageal reflux ( n = 1). All procedures were completed successfully with one Clavien–Dindo Grade IIIb complication (fascial dehiscence). No Grade 4 or 5 complications were observed. At 3‐month follow‐up, complete symptom resolution was achieved in six out of nine patients (67%). Complete symptom resolution at 1 year follow‐up was achieved in eight out of nine patients (89%). Conclusion: Substantial symptom improvement and acceptable and transient postoperative morbidity indicate that Roux‐en‐Y reconstruction is a viable treatment option for patients with persistent functional complaints following esophagectomy with gastric conduit reconstruction.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Distribution of semi-quantitative VEGF expression
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Distribution of semi-quantitative VEGF expression
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Data from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Purpose:The ability to identify residual tumor tissues in patients with locally advanced esophageal cancer following neoadjuvant chemoradiotherapy (nCRT) is essential for monitoring the treatment response. Using the fluorescent tracer bevacizumab-800CW, we evaluated whether ultrasound-guided quantitative fluorescent molecular endoscopy (US-qFME), which combines quantitative fluorescence molecular endoscopy (qFME) with ultrasound-guided needle biopsy/single-fiber fluorescence (USNB/SFF), can be used to identify residual tumor tissues in patients following nCRT.Experimental Design:Twenty patients received an additional endoscopy procedure the day before surgery. qFME was performed at the primary tumor site (PTS) and in healthy tissue to first establish the optimal tracer dose. USNB/SFF was then used to measure intrinsic fluorescence in the deeper PTS layers and lymph nodes (LN) suspected for metastasis. Finally, the intrinsic fluorescence and the tissue optical properties—specifically, the absorption and reduced scattering coefficients—were combined into a new parameter called omega.Results:First, a 25-mg bevacizumab-800CW dose allowed for clear differentiation between the PTS and healthy tissue, with a target-to-background ratio (TBR) of 2.98 (IQR, 1.86–3.03). Moreover, we found a clear difference between the deeper esophageal PTS layers and suspected LN compared to healthy tissues, with TBR values of 2.18 and 2.17, respectively. Finally, our new parameter, omega, further improved the ability to differentiate between the PTS and healthy tissue.Conclusions:Combining bevacizumab-800CW with US-qFME may serve as a viable strategy for monitoring the response to nCRT in esophageal cancer and may help stratify patients regarding active surveillance versus surgery.
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Purpose:The ability to identify residual tumor tissues in patients with locally advanced esophageal cancer following neoadjuvant chemoradiotherapy (nCRT) is essential for monitoring the treatment response. Using the fluorescent tracer bevacizumab-800CW, we evaluated whether ultrasound-guided quantitative fluorescent molecular endoscopy (US-qFME), which combines quantitative fluorescence molecular endoscopy (qFME) with ultrasound-guided needle biopsy/single-fiber fluorescence (USNB/SFF), can be used to identify residual tumor tissues in patients following nCRT.Experimental Design:Twenty patients received an additional endoscopy procedure the day before surgery. qFME was performed at the primary tumor site (PTS) and in healthy tissue to first establish the optimal tracer dose. USNB/SFF was then used to measure intrinsic fluorescence in the deeper PTS layers and lymph nodes (LN) suspected for metastasis. Finally, the intrinsic fluorescence and the tissue optical properties—specifically, the absorption and reduced scattering coefficients—were combined into a new parameter called omega.Results:First, a 25-mg bevacizumab-800CW dose allowed for clear differentiation between the PTS and healthy tissue, with a target-to-background ratio (TBR) of 2.98 (IQR, 1.86–3.03). Moreover, we found a clear difference between the deeper esophageal PTS layers and suspected LN compared to healthy tissues, with TBR values of 2.18 and 2.17, respectively. Finally, our new parameter, omega, further improved the ability to differentiate between the PTS and healthy tissue.Conclusions:Combining bevacizumab-800CW with US-qFME may serve as a viable strategy for monitoring the response to nCRT in esophageal cancer and may help stratify patients regarding active surveillance versus surgery.
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Material S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Description of resection specimen and determination of optical properties
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Description of resection specimen and determination of optical properties
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Representativeness of Study Participants
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Representativeness of Study Participants
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Overview of the absorption and scattering parameters used for tissue characterisation
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Overview of the absorption and scattering parameters used for tissue characterisation
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Distribution of semi-quantitative VEGF expression
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Distribution of semi-quantitative VEGF expression
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Overview of the absorption and scattering parameters used for tissue characterisation
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Overview of the absorption and scattering parameters used for tissue characterisation
- Open Access
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Representativeness of Study Participants
- 1 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Ultrasound-Guided Quantitative Fluorescence Molecular Endoscopy for Monitoring Response in Patients with Esophageal Cancer Following Neoadjuvant Chemoradiotherapy
Representativeness of Study Participants